SCHEMBL731053

SCHEMBL731053

COC(=O)c1cc(OS(=O)(=O)C(F)(F)F)cc(-c2ccccc2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA9 Q16790 1/20 0.45
EGFR P00533 1/20 0.44
TSHR P16473 1/20 0.44
SDHB P21912 1/20 0.43
PTGS2 P35354 1/20 0.42
ACLY P53396 4/20 0.42
PLAU P00749 2/20 0.42
LDHA P00338 1/20 0.42
PDK2 Q15119 1/20 0.41
ADORA2A P29274 1/20 0.40
ADORA1 P30542 1/20 0.40
BRD4 O60885 1/20 0.40
GABRG2 P18507 1/20 0.40
GABRB3 P28472 1/20 0.40
GABRA5 P31644 1/20 0.40
GABRA3 P34903 1/20 0.40
KAT6A Q92794 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL732952 0.85 NOTUM (0.45) CA12CA1CA2CA9TSHR
SCHEMBL4391166 0.85 NOTUM (0.45) CA12CA1CA2CA9TSHR
SCHEMBL10206864 0.84 TSHR (0.44) TSHRPDK2KAT6A
SCHEMBL14881384 0.84 CA12 (0.49) CA12CA1CA2CA9SDHB
SCHEMBL24736909 0.82 STS (0.43) CA12CA1CA2CA9PLAU
SCHEMBL30116304 0.82 STS (0.43) CA12CA1CA2CA9PLAU
SCHEMBL730884 0.81 KDM4E (0.45) CA12CA1CA2CA9TSHR
SCHEMBL14150405 0.81 RXRA (0.56) CA1CA2EGFRTSHRBRD4
SCHEMBL9957224 0.81 ADORA2A (0.49) CA12CA1CA2CA9SDHB
SCHEMBL8235722 0.81 CYP4F2 (0.47) CA1CA2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2120569-B1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME (US) 2013-08-14 EP disclosed
EP-2120569-B1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME (US) 2013-08-14 EP disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
EP-2120569-A2 SPIROCHROMANON DERIVATIVES Merck & Co., Inc. (US) 2009-11-25 EP disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
WO-2008088692-A2 SPIROCHROMANON DERIVATIVES MERCK & CO., INC. (US) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270436-A1 SPIROCHROMANON DERIVATIVES AKR1C3, CBR3, AKR1C4 CA12 3525/4885CA1 2203/4885CA2 1987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.